

SPL/NSE/2012-13

July 7, 2012

National Stock Exchange of India Limited
"EXCHANGE PLAZA"
Bandra-Kurla Complex,
Bandra (E),
MUMBAI-400 051
Fax No. 022-2659 8237/38,
022-2659 8347/48

SCRIPT CODE: 532516

Sub: COMPLIANCE OF THE LISTING AGREEMENT

Dear Sir,

In compliance with the listing agreement please find attached audited results for the year ended 31st March, 2012 .

This is for your information and records please.

Thanking you,

Yours faithfully,
For **Surya Pharmaceutical Limited**



RAJIV GOYAL
(Chairman & Managing Director)

Encl: As above

Surya Pharmaceutical Limited

Corporate Office : SCO 164-65, Sector 9-C, Madhya Marg, Chandigarh-160 009 (INDIA)
Tel : +91 172 5005000 FAX: +91 172 5076000 Email : info@suryapharma.com ; Website : www.suryapharma.com
Regd. Office : 1596, 1st Floor, Bhagirath Palace, Chandni Chowk, Delhi - 110 006 (INDIA)

M/S SURYA PHARMACEUTICAL LIMITED

STATEMENT OF AUDITED RESULTS AS AT 31ST MARCH 2012

	Year to date figures	
	for the current period ended (31.03.2012)	for the previous year ended (31.03.2011)
	Audited	Audited
I Revenue from operations	16,22,94,90,994	16,00,41,74,949
II Other Income	(37,98,12,715)	2,67,27,694
III Total Revenue (I + II)	15,84,96,78,280	16,03,09,02,643
IV Expenses		
i Cost of Material Consumed	15,97,15,37,191	15,04,25,11,301
ii Changes in Inventories of FG,WIP and Stock in Trade	57,35,44,724	(2,73,26,08,409)
iii Other Manufacturing Expenses	38,71,91,705	40,89,78,060
iv Employee Benefit Expense	40,91,10,741	40,35,98,928
v Finance Cost	1,65,84,83,860	97,78,06,532
vi Depreciation and Amortisation Expense	34,61,73,609	26,54,69,543
vii Other Expenses	43,58,82,383	34,79,85,748
Total Expense	19,78,19,24,214	14,71,37,41,703
V Profit before exceptional and extraordinary items and tax (III - IV)	(3,93,22,45,934)	1,31,71,60,940
VI Exceptional Items	-	-
VII Profit before extraordinary items and tax (V - VI)	(3,93,22,45,934)	1,31,71,60,940
VIII Extraordinary Items	-	-
IX Profit before Tax (VII - VIII)	(3,93,22,45,934)	1,31,71,60,940
X Tax Expense		
i Current Tax	-	26,25,10,175
ii Deferred Tax	(1,20,72,45,734)	6,14,32,752
iii MAT Credit Entitlement	-	(83,60,640)
XV Profit (Loss) for the period	(2,72,50,00,200)	1,00,15,78,653
XVI Prior Period Items	-	1,24,59,989
Proposed Dividend(Including DDT)	65,51,575	3,25,17,372
XVII Earnings per equity share of Rs.1/- each		
i Basic	(13.44)	5.13
ii Diluted	(13.44)	5.13

Particulars	Year to date figures	
	for the current period ended (31.03.2012)	for the previous period ended (31.03.2011)
	Audited	Audited
A PARTICULARS OF SHAREHOLDING		
1 Public Shareholding		
- Number of Shares	125488750	125488750
- Percentage of Shareholding	61.89	65.1
2 Promoter and Promoter Group Shareholding:		
a) Pledged/Encumbered		
- No. of Shares	76094880	47369480
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	98.49	70.42
- Percentage of Shares (as a % of the total share Capital of the Company)	37.53	24.58
b) Non-Encumbered		
- No. of Shares	1168750	19894150
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	1.51	29.58
- Percentage of Shares (as a % of the total share Capital of the Company)	0.58	10.32

Notes :-

- 1) Previous year figures have been re-grouped and re-arranged wherever considered necessary.
- 2) The above results have been reviewed by the Audit Committee on 06.07.2012 and taken on record by the Board of Directors at its meeting held on 07.07.2012
- 3) The Company has made an reference to CDR on 10-03-2012 and the case has been admitted.
- 4) As per recommendations by stock auditor appointed by Bankers, the effect of impairment of stock has been taken into account while preparing annual audited accounts as on 31.03.2012
- 5) As the company operates in one segment; hence information as per AS 17 is not required to be disclosed.

For and on Behalf of Board of Directors
For Surya Pharmaceutical Limited


Rajiv Goyal
(Chairman & Managing Director)

7th July, 2012
Chandigarh

M/S SURYA PHARMACEUTICAL LIMITED				
Regd office : 1596 , 1st Floor , Bhagirath Palace , Chandni chowk , Delhi - 110006				
STATEMENT OF ASSETS & LIABILITIES AT 31ST MARCH 2012				
			Year to date figures for the current period ended (31.03.2012)	Year to date figures for the previous year ended (31.03.2011)
			Audited	Audited
I	EQUITY AND LIABILITIES			
1	ShareHolders' Funds			
	i	Share Capital	20,27,52,380	19,27,52,380
	ii	Reserves & Surplus	2,27,20,44,966	4,94,10,96,741
	iii	Money Received against share warrants	-	6,56,25,000
		Shareholder's Funds	2,47,47,97,346	5,19,94,74,121
2	Share Application Money Pending Allotment		-	-
3	Non Current Liabilities			
	i	Long Term Borrowings	2,19,53,04,807	2,65,08,19,109
	ii	Deferred tax Liabilities (Net)	-	19,36,04,496
	iii	Other Long Term Liabilities	21,18,39,107	44,64,77,239
	iv	Long term provisions	2,44,80,592	2,18,78,529
		Non Current Liabilities	2,43,16,24,506	3,31,27,79,373
4	Current Liabilities			
	i	Short Term Borrowings	14,36,24,46,460	11,07,41,80,481
	ii	Trade Payables	46,33,93,699.90	68,67,87,902
	iii	Other Current Liabilities	1,53,48,84,609	1,34,64,76,532
	iv	Short Term Provisions	94,11,330	3,85,81,385
		Current Liabilities	16,37,01,36,099	13,14,60,26,300
		EQUITY AND LIABILITIES	21,27,65,57,951	21,65,82,79,794
II	ASSETS			
	Non Current Assets			
1	Fixed Assets			
	i	Tangible Assets	7,16,24,71,593	4,02,95,73,153
	ii	Intangible Assets	11,63,93,203	1,42,91,230
	iii	Capital Work in Progress	7,40,00,123	2,32,06,12,193
		Fixed Assets	7,35,28,64,919	6,36,44,76,576
2	Non Current Investments		33,83,26,093	20,59,96,139
3	Deferred Tax (Net)		1,01,36,41,238	-
4	Long Term Loans and Advances		85,87,29,883	90,60,988
5	Other Non Current Assets		-	-
		Non Current Assets	2,21,06,97,214	21,50,57,127
	Current Assets			
	i	Current Investments	20,46,275	5,21,46,275
	ii	Inventories	8,12,25,47,871	10,40,63,25,036
	iii	Trade Receivables	2,36,21,09,198	2,90,84,87,488
	iv	Cash and Cash Equivalents	9,88,31,198	15,48,02,238
	v	Short Term loans and Advances	76,16,14,915	70,73,63,961
	vi	Other Current Assets	36,58,46,361	84,96,21,093
		Current Assets	11,71,29,95,818	15,07,87,46,091
		ASSETS	21,27,65,57,951	21,65,82,79,794

For SURYA PHARMACEUTICAL LTD.

Rajiv Goyal
RAJIV GOYAL
Managing Director